Mode of action
- Helps the body release insulin when blood sugar is high
- Lowers appetite, so you eat less
- Slows stomach emptying, mostly early in treatment

GLP-1 receptor agonist for long-term weight management.

Long-term weight management in eligible adults with obesity or overweight and a weight-related health problem.
*7.2 mg: certain markets and formulations only.
Injection under the skin (subcutaneous). In the main trial: once a week, from 0.25 mg up to 2.4 mg by week 16.
| Receptor | What it does | |
|---|---|---|
| GLP-1 | Lowers appetite, slows stomach emptying, helps insulin release | Yes |
| GIP | Helps insulin release and appetite and energy control | No |
| Glucagon | Being studied for raising energy use | No |
Source: STEP 1, 68 weeks, 1,961 adults without diabetes (NEJM 2021). Share of people reaching each weight-loss goal.
Common stomach effects in trials: nausea, vomiting, diarrhea and constipation. Doctors also check for dehydration, gallbladder disease and pancreatitis.
Source: WEGOVY prescribing information (DailyMed); STEP 1 (NEJM 2021). The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.